Pharmacokinetics and safety of evogliptin in hepatically impaired patients.

Taegon HongByung Hak JinChoon Ok KimByung Won YooDasohm KimJung Il LeeBeom Kyung KimSang Hoon AhnDo Young KimJun Yong ParkMin Soo Park

Published in: British journal of clinical pharmacology (2020)

Although evogliptin exposure was increased in patients with moderate hepatic impairment, the increase is unlikely to affect safety and efficacy adversely, and no dose adjustment is warranted.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
high intensity
patient reported outcomes